Simile vs a2z Radiology AI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $100M Series A in February 2026 led by Index Ventures with Fei-Fei Li and Andrej Karpathy backing, after CVS Health and Telstra adopted its AI digital twin platform to replace focus groups.
About
Simile is a Stanford spinout founded in 2025 by Percy Liang, Michael Bernstein, and Joon Sung Park that built the first AI simulation of society — a platform populated by generative agents trained on real human behavioral data to faithfully simulate how specific demographic segments make decisions. Enterprises use Simile to replace slow, expensive focus groups and A/B tests with instant, scalable AI simulations. Early enterprise customers include CVS Health for inventory optimization and Telstra for customer strategy decisions.
a2z Radiology AI raised $20M in 2025 for its whole-body AI that simultaneously screens for 24+ conditions across CT scans — from incidental cancers to cardiovascular risk — in a single automated read.
About
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disease, aortic aneurysm, bone density loss, and organ abnormalities. The AI acts as a second reader that radiologists can use to catch incidental findings that fall outside the primary reason for a scan — a major source of missed diagnoses.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.